New-base injection with yew alcohol was removed from the net! After the quality is not up to standard, the large market is difficult to guarantee!

Following the loss of collection qualification, the new-base injection with yew alcohol (albumin binding type) was suspended by Shaanxi Province, the quality of substandard shadow, The loss of the profits or incalculable on the drug at time MeiMei Shiguibao..New base injection with yew alcohol quality is not up to standard, a large market is difficult to protect!March 25, the State Drug Administration issued a "announcement on the suspension of import, sale and use of Celgene Corporation injection of yew alcohol (albumin-combined type) (2020 No44)," today, Shaanxi Province Public Resources Trading Center announced that the product suspended from the networkAnd shortly after the announcement of the FDA announcement, the Joint Procurement Office, which organizes the centralized procurement and use of drugs, has revoked the eligibility for the new base injection of yew alcoholthe State Drug Administration banned the import, sale and use of new-based injection of yew alcohol (albumin-combined type), because some of the key production facilities of the drug do not meet the basic requirements of quality management of China's pharmaceutical production, there are problems such as the production process sterile safeguards are not in placeIf the new base in a short period of time does not rectify, it is expected that the other regions will be sent back the network, this drug will lose a large area of the Chinese market in the short termNew Base is the original pharmaceutical manufacturer with the injection of yew alcohol (albumin-combined type), which occupies an important market in ChinaIn the absence of a national collection, minet data show that the new base pharmaceutical / Baiji Shenzhou injection with yew alcohol (albumin combination type) in 2018 public hospital sales scale of 721 million yuan, the unit price is 5600 yuan 100 mg per unit, stone medicine European meaning 146 million yuan, Hengrui Pharmaceutical only 14.55 million yuanwith the 2018 stone medicine O'Yi, Hengrui Pharmaceuticals and Qilu Pharmaceuticals generic drugs have been listed in China, injection with yew alcohol (albumin-combined) market pattern has changed significantlyData show that in 2019, the market share of Shipharmaceutical Europe, Hengrui Pharmaceuticals has far exceeded the new base, Qilu Pharmaceutical's generic drugs listed late, accounting for a relatively low2019, Xinji will become a wholly owned subsidiary of Boxei SquibbData show that the injection of yew alcohol (albumin-combined type) in the 2019 annual report of The Times Meishi Guibao sales of 166 million U.Sdollars, about 1.13 billion yuanonce the loss of the network qualification, coupled with the second batch of collection will be launched in April, it can be expected that the profits of The Times Squibb in this drug will be greatly affectedthe national collection, generic drug replacement obvious
the second batch of national collection and bidding rules mentioned that the selected enterprises can not supply, should be from this collection of other selected enterprises to determine the replacement of the supply enterprises in the January 17 bidding, there are four enterprises involved in the injection of yew alcohol (albumin-combined type) bidding, the last stone medicine Oyi, Hengrui, China Resources Pharmaceuticals (New Base / Baiji Shenzhou) 3 finalists, Qilu because of the price of 1828 yuan and lost the bid therefore, the industry speculated that Hengrui, Stone Pharmaceuticals is likely to replace the new base, including the new base after the low-cost blood supply area and procurement volume in accordance with the rules, the actual selection of enterprises in the country for 3, for the first year agreed to purchase 70% of the calculation base, calculated, injection with yew alcohol (albumin binding type) the first year agreed procurement volume of 958.26 million units The provinces supplied by the new base are Beijing, Tianjin, Zhejiang, Jiangxi, Hubei, Hainan, Chongqing, Tibet, Gansu, Xinjiang (including the Army Corps), the procurement volume of 437.41 million units, according to the new base injection with yew alcohol (albumin binding type) selected price calculation, the cumulative amount of about 50 million yuan the state to carry out drug band procurement aimed at combating inflated drug prices, accelerating the replacement of generic drugs with original drugs, reducing drug prices, but also to the benefit of the people The active participation of multinational pharmaceutical companies throughout the country can be seen in their determination to cater to the market At this time, if the original research drug enterprises, if the quality of drugs, the drug market will undoubtedly be filled by domestic drugs and previously pointed out in the collection rules, enterprises have quality problems, the next two years may not be able to carry out China's centralized procurement declaration of drugs It can be seen that the loss of the time is small, the loss of market share is difficult to predict.